Table 5 Clinical and laboratory characteristic of (A) 148 patients with PBC at two time points (follow-up: 8 ± 4 years)—Szczecin cohort, (B) 214 patients with PBC at two time points (follow-up: 4 ± 2 years)—Warsaw cohort
Variables | Subject characteristics | P | |
|---|---|---|---|
At diagnosis | Follow-up | ||
(A) | |||
N | 148 | ||
Gender, female/male (%) | 130 (88%)/18 (12%) | ||
Cirrhosis (%) | 59 (40%) | 81 (55%) | < 0.001 |
Bilirubin (mg/dl) | 4 (0.3–40.5) | 3 (0.3–29.3) | 0.598 |
ALT (U/L) | 85 (10–660) | 52 (10–176) | < 0.001 |
AST (U/L) | 84 (15–931) | 64 (15–236) | 0.003 |
ALP (U/L) | 376 (37–1899) | 245 (52–979) | < 0.001 |
GGT (U/L) | 341 (17–2755) | 224 (14–1952) | < 0.001 |
(B) | |||
N | 214 | ||
Gender, female/male (%) | 199 (93%)/15 (7%) | ||
Cirrhosis (%) | 102 (48%) | 148 (69%) | < 0.001 |
Bilirubin (mg/dl) | 1.2 (0.2–22.0) | 0.75 (0.16–31.2) | 0.218 |
ALT (U/L) | 88 (11–1742) | 36 (11–881) | < 0.001 |
AST (U/L) | 86 (17–1149) | 35 (9–194) | < 0.001 |
ALP (U/L) | 369 (56–1620) | 135 (42–1141) | < 0.001 |
GGT (U/L) | 357 (34–2670) | 69 (10–4255) | < 0.001 |